Anti-human tie-2 antibody

Patent metadata

Field	Value
Publication number	US-9683051-B2
Application number	US-201615134803-A
Country	US
Kind code	B2
Filing date	Apr 21, 2016
Priority date	Jul 15, 2014
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.

First claim

The invention claimed is:

1. An anti-human Tie2 antibody or an antigen-binding fragment thereof, comprising four heavy chain variable regions and four light chain variable regions, wherein
the heavy chain variable region comprises CDR1 consisting of the amino acid sequence of the amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of the amino acid numbers 50 to 66 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of the amino acid numbers 99 to 111 of SEQ ID NO: 2;
the light chain variable region comprises CDR1 consisting of the amino acid sequence of the amino acid numbers 24 to 39 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of the amino acid numbers 55 to 61 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of the amino acid numbers 94 to 102 of SEQ ID NO: 4; and
the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites.

2. The anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 1 , selected from the group consisting of:
(i) an anti-human Tie2 antibody or an antigen-binding fragment thereof, comprising four heavy chain variable regions and four light chain variable regions, in which
the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2,
the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, and
the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites; and
(ii) an anti-human Tie2 antibody or an antigen-binding fragment thereof wherein the antibody or the antigen-binding fragment thereof has undergone pyroglutamylation at the N-terminal of the heavy chain variable region of the anti-human Tie2 antibody or the antigen-binding fragment thereof of (i).

3. A pharmaceutical composition comprising the anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 2 and a pharmaceutically acceptable excipient.

4. A method for treating diabetic macular edema, diabetic retinopathy, or critical limb ischemia, comprising administering a therapeutically effective amount of the anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 2 .

5. The anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 2 , comprising an anti-human Tie2 antibody or an antigen-binding fragment thereof, comprising four heavy chain variable regions and four light chain variable regions, in which
the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2,
the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, and
the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites.

6. An anti-human Tie2 antibody or an antigen-binding fragment thereof, produced by a method comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express a tetravalent anti-human Tie2 antibody or an antigen-binding fragment thereof:
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 5 and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof according to claim 5 ;
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 5 and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof according to claim 5 ; and
(c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human Tie2 antibody or the antigen-binding fragment thereof according to claim 5 and a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof according to claim 5 .

7. The anti-human Tie2 antibody according to claim 1 , wherein the antibody comprises two heavy chains and four light chains;
each heavy chain comprises two structures consisting of a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of the amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of the amino acid numbers 50 to 66 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of the amino acid numbers 99 to 111 of SEQ ID NO: 2 and a CH1 region, a CH2 region, and a CH3 region, and the carboxy terminus (C terminus) of one of the structures is linked to the amino terminus (N terminus) of the other structure through a linker; and
each light chain comprises a light chain variable region comprising CDR1 consisting of the amino acid sequence of the amino acid numbers 24 to 39 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of the amino acid numbers 55 to 61 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of the amino acid numbers 94 to 102 of SEQ ID NO: 4, and a light chain constant region.

8. The anti-human Tie2 antibody according to claim 7 , selected from the group consisting of:
(i) an anti-human Tie2 antibody comprising two heavy chains and four light chains, in which
each heavy chain comprises two structures consisting of a heavy chain variable region consisting of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2 and a CH1 region, a CH2 region, and a CH3 region, and the C terminus of one of the structures is linked to the N terminus of the other structure through a linker; and
each light chain comprises a light chain variable region consisting of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, and a light chain constant region; and
(ii) an anti-human Tie2 antibody wherein of the antibody has undergone pyroglutamylation at the N-terminal of the heavy chain variable region of the anti-human Tie2 antibody or the antigen-binding fragment thereof of (i).

9. The anti-human Tie2 antibody according to claim 8 , selected from (i) or (ii) below:
(i) an anti-human Tie2 antibody comprising two heavy chains consisting of the amino acid sequence shown by SEQ ID NO: 2 and four light chains consisting of the amino acid sequence shown by SEQ ID NO: 4; or
(ii) an anti-human Tie2 antibody comprising two heavy chains consisting of the amino acid sequence in which glutamic acid of the amino acid number 1 of SEQ ID NO: 2 is modified to pyroglutamic acid and/or lysine of the amino acid number 679 of SEQ ID NO: 2 is deleted and four light chains consisting of the amino acid sequence shown by SEQ ID NO: 4.

10. The anti-human Tie2 antibody according to claim 9 , comprising two heavy chains consisting of the amino acid sequence shown by SEQ ID NO: 2 and four light chains consisting of the amino acid sequence

Assignees

• Astellas Pharma Inc

Inventors

• Kamohara Masazumi
• Yagi Shigenori
• Ishii Yoshinori
• Nara Hiromi

Classifications

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C07K16/2863 Primary

  against receptors for growth factors, growth regulators · CPC title